Seagen (SGEN) PT Lowered to $146 at Wolfe Research
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Seagen (SGEN) Stock Plunges on Weak Outlook and Q4 Miss, Analysts Lower Price Targets
February 10, 2022 7:14 AM ESTShares of Seagen (NASDAQ: SGEN) plummeted more than 16.5% in premarket trading on Thursday after the biotech company reported Q4 2021 and FY 2021 financial results.
The company reported that Q4 revenue climbed to $369.2 million, down from $601.3 million in the year-ago period. FY 2021 revenue came in at $1.57 billion, way below $2.17 billion reported in Q4 2020. Analysts were calling for Q4 EPS of ($0.82) on sales of $406.87 million.
Seagen sees 2022 revenue of $1.48-1.545 billion, versus the consensus of $2.16 billion.
Total net product... More
Seagen (SGEN) PT Lowered to $170 at H.C. Wainwright
February 10, 2022 6:40 AM ESTH.C. Wainwright analyst Andrew Fein lowered the price target on Seagen (NASDAQ: SGEN) to $170.00 (from $200.00) while maintaining a Buy rating following results.
The analyst commented, "Yesterday, Seagen delivered revenue guidance which fell below consensus estimates suggestive of incremental to flat sales growth... More
